INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 438s ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Corporate insider
AR

Anderson Raymond

DirectorCIK 0001362489

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 4
Max Insider Score21
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
7
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M$42K
1,402 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Monopar TherapeuticsDirector · Nov 4, 2026
10
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M
$52K
1,740 sh
Nov 2, 2026
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

10
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$14K
200 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

21
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$105K
1,502 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
1,402 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

17
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$56K
840 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

14
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$40K
600 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
1,740 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence